Comparative Pharmacology
Head-to-head clinical analysis: SULSOXIN versus TRIMETHOPRIM SULFAMETHOXAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULSOXIN versus TRIMETHOPRIM SULFAMETHOXAZOLE.
SULSOXIN vs Trimethoprim-Sulfamethoxazole
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs) and disrupting peptidoglycan cross-linking.
Sulfamethoxazole inhibits dihydropteroate synthase, blocking para-aminobenzoic acid incorporation into dihydrofolate; trimethoprim inhibits dihydrofolate reductase, preventing tetrahydrofolate formation. Sequential blockade of folate synthesis.
500 mg orally 4 times daily for 10-14 days (or 1 g orally 4 times daily for severe infections).
Oral: 160 mg TMP/800 mg SMX every 12 hours; IV: 8-10 mg/kg/day (based on TMP) in 2-4 divided doses
None Documented
None Documented
8 hours (terminal) — extends in renal impairment (up to 24 hours in CrCl <30 mL/min); requires dose adjustment
Trimethoprim: 8-10 hours (normal renal function); prolonged to 24-30 hours in severe renal impairment (CrCl <10 mL/min). Sulfamethoxazole: 9-11 hours; prolonged in renal failure. The combination retains a half-life of ~10-12 hours in healthy adults, requiring dose adjustment in renal impairment.
Renal: 70% (unchanged); biliary/fecal: 20%; minor hepatic metabolism (<10%)
Trimethoprim: 50-60% excreted unchanged in urine via glomerular filtration and tubular secretion; 10-20% as metabolites. Sulfamethoxazole: 20-30% excreted unchanged in urine; 50-70% as N4-acetylated metabolite. Both undergo minimal biliary/fecal elimination (<5% total).
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic